InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

InflaRx N.V.NASDAQ: IFRX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of €88.62K fell 22.1% year over year, behind the -20.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 19.2% from the prior quarter. Over 3 fiscal years it compounded at -12.3% a year.

Context

  • Depreciation & amortization amounted to 1373.7% of revenue in FY2025, up 1081.1 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -22.1% toward the trailing-twelve-month pace of -20.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€88.62K+19.2% QoQ
Last fiscal yearDec 2025
€402.93K-16.9% YoY
LTMMar 2026
€377.74K-20.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.1%——
1 year-16.9%——
3-year CAGR-12.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the cash flow

Latest · FY2025
402.93K EUR
Year-over-year change
-16.9%
4-year CAGR
-11.9%

Depreciation & Amortization vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -20.5% is the lowest of 8, against a peer median of +9.6%.
  • Depreciation & amortization amounts to 1287.9% of revenue for IFRX, versus a peer median of 593.7%.
IFRX Competitors
Depreciation & Amortization for IFRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$6.7M USD-8.9%+8.8%6.7%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.71M USD+9.6%+30.9%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$1.56M USD+35.6%-2.9%823.2%
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.4%1100.0%
IMAImageneBio IncLTM Mar 2026$616K USD+72.1%-24.1%—
IFRXInflaRx N.V.LTM Mar 2026€377.74K EUR-20.5%-12.3%1287.9%
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$16.88K USD+36.5%+20.6%—
Peer median (excluding IFRX) —+9.6%+6.3%593.7%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(43.83M)
Depreciation & Amortization669.43K596.6K567.78K485.11K402.93K
Deferred Income Tax1.16M0000
Stock-Based Compensation4.33M6.04M3.41M4.07M0
Change in Working Capital1.54M(9.77M)1M(2.28M)4.66M
Accounts Receivables00002.12M
Inventory00(11.37M)4.47M6.63M
Accounts Payables316.11K(3.52M)00(5.76M)
Other Working Capital1.22M(6.25M)12.37M(6.75M)1.68M
Other Non-Cash Items(2M)(1.13M)(131.29K)(4.76M)4.84M
Operating Cash Flow(39.94M)(33.74M)(37.81M)(48.56M)(33.92M)
Capital Expenditures(37.78K)(162.39K)(81.1K)(46.87K)(111.13K)
Acquisitions (Net)37.78K(19.52M)000
Purchases of Investments(97.52M)(64.47M)(104.05M)(35.34M)(44.28M)
Sales of Investments71.6M84M86.44M87.75M47.5M
Other Investing Activities(37.78K)19.52M01(3)
Investing Cash Flow(25.95M)19.36M(17.7M)52.36M3.11M
Debt Repayment(360.64K)(364.43K)(373.98K)(388.11K)(357.58K)
Common Stock Issued65.14M2.35M56.48M1.1M32.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.2M)(47.74K)(3.12M)(323.73K)14.11K
Financing Cash Flow61.58M1.94M52.99M386.45K32M
Effect of Forex Changes4.59M2.46M(974.1K)1.41M(1.37M)
Net Change in Cash281.31K(9.98M)(3.5M)5.61M(179.66K)
Free Cash Flow(39.97M)(33.91M)(37.89M)(48.6M)(34.03M)

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.